Patents Assigned to TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY
  • Patent number: 11040087
    Abstract: Provided is a therapeutic agent that effectively acts on a disease associated with abnormal glycosylation of dystroglycan. Also provided is a testing method for diseases associated with abnormal glycosylation of dystroglycan. Specifically, provided is a therapeutic agent for diseases associated with abnormal glycosylation of dystroglycan, containing CDP-ribitol as an active ingredient. Ribitol-phosphate is important in the glycan structure of dystroglycan. In order for ribitol-phosphate to be incorporated into a dystroglycan glycan, a material therefor (sugar donor) is required. In the present invention, it has been found for the first time that CDP-ribitol serves as the sugar donor. It has been confirmed that the glycan of ISPD-deficient cells can be restored by administering CDP-ribitol. Thus, the present invention, which allows CDP-ribitol to be utilized for supplementation therapy, has been completed.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: June 22, 2021
    Assignees: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY, OSAKA PREFECTURAL HOSPITAL ORGANIZATION
    Inventors: Tatsushi Toda, Kazuhiro Kobayashi, Motoi Kanagawa, Tamao Endo, Hiroshi Manya, Yoshinao Wada, Michiko Tajiri
  • Publication number: 20190247450
    Abstract: Provided is an agent or a food or drink for inhibiting the onset of overall disease. An agent for inhibiting a decrease in a disease-free rate comprises a lactic acid bacterium as an active ingredient.
    Type: Application
    Filed: October 30, 2017
    Publication date: August 15, 2019
    Applicants: KABUSHIKI KAISHA YAKULT HONSHA, TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY
    Inventors: Yukitoshi AOYAGI, Satoshi MATSUBARA, Yusuke HONDA, Ryuta AMAMOTO, Koji MIYAZAKI
  • Patent number: 10160949
    Abstract: The present invention addresses the problem of providing an agent for improving sperm-motility, in particular, an agent for improving forward-sperm-motility, for use on reduced-motility sperm in male infertility treatment. Prepared is a gaseous agent for improving sperm-motility consisting of a gas that contains hydrogen molecules in the amount of 1% (v/v) or higher, for example, a gas that contains hydrogen molecules in an amount of between 45 and 55% (v/v), or a liquid agent for improving sperm-motility consisting of a liquid such as physiological saline, a culture solution, or a buffer solution containing hydrogen molecules in the amount of 1% or higher of the saturation solubility thereof, for example, a liquid in which hydrogen molecules have been dissolved by bubbling.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: December 25, 2018
    Assignees: Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
    Inventors: Naoki Yamashita, Kumiko Nakata, Ikuroh Ohsawa
  • Patent number: 9618502
    Abstract: The object of the present invention is to provide a method for screening a substance involved in a metabolic shift of skeletal muscle, and a kit for screening a substance involved in a metabolic shift of skeletal muscle. The object can be solved by a muscle stem cell or myoblast comprising at least one myosin-heavy chain fusion gene selected from the group consisting of a myosin-heavy chain I fusion gene wherein a myosin-heavy chain I gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IIa fusion gene wherein a myosin-heavy chain IIa gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IId/x fusion gene wherein a myosin-heavy chain IId/x gene and a fluorescent protein or photoprotein gene are fused, and a myosin-heavy chain IIb fusion gene wherein a myosin-heavy chain IIb gene and a fluorescent protein or photoprotein gene are fused.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: April 11, 2017
    Assignee: Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
    Inventor: Kazuhiro Shigemoto
  • Patent number: 9568469
    Abstract: The object of the present invention is to provide a method for screening a substance involved in a metabolic shift of skeletal muscle, and a kit for screening a substance involved in a metabolic shift of skeletal muscle. The object can be solved by a muscle stem cell or myoblast comprising at least one myosin-heavy chain fusion gene selected from the group consisting of a myosin-heavy chain I fusion gene wherein a myosin-heavy chain I gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IIa fusion gene wherein a myosin-heavy chain IIa gene and a fluorescent protein or photoprotein gene are fused, a myosin-heavy chain IId/x fusion gene wherein a myosin-heavy chain IId/x gene and a fluorescent protein or photoprotein gene are fused, and a myosin-heavy chain IIb fusion gene wherein a myosin-heavy chain IIb gene and a fluorescent protein or photoprotein gene are fused.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: February 14, 2017
    Assignee: Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology
    Inventor: Kazuhiro Shigemoto
  • Patent number: 8710193
    Abstract: Provided is a therapeutic method exclusively targeting an amyloid ? protein (A?) having a specific turn structure of A?. Specifically provided is an antibody which specifically recognizes an amyloid ? having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid ?, an assay kit for a toxic conformer of amyloid ?, a diagnostic for Alzheimer's disease, etc.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: April 29, 2014
    Assignees: Kyoto University, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Immuno-Biological Laboratories Co., Ltd.
    Inventors: Kazuhiro Irie, Kazuma Murakami, Yuichi Masuda, Takahiko Shimizu, Takuji Shirasawa, Tsutomu Seito
  • Publication number: 20120219552
    Abstract: Provided is a therapeutic method exclusively targeting an amyloid ? protein (A?) having a specific turn structure of A?. Specifically provided is an antibody which specifically recognizes an amyloid ? having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid ?, an assay kit for a toxic conformer of amyloid ?, a diagnostic for Alzheimer's disease, etc.
    Type: Application
    Filed: October 18, 2010
    Publication date: August 30, 2012
    Applicants: KYOTO UNIVERSITY, IMMUNO-BIOLOGICAL LABORATORIES CO., LTD., TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY
    Inventors: Kazuhiro Irie, Kazuma Murakami, Yuichi Masuda, Takahiko Shimizu, Takuji Shirasawa, Tsutomu Seito